Dakota Private Markets is a highly curated database of GPs, Funds, Private Companies, Performance and Benchmarks across all asset classes. Click to learn more.
Behind every transformative therapeutic breakthrough is a venture firm willing to take bold scientific risk. Today’s leading biotech investors do more than deploy capital. They incubate platforms, shape R&D strategy, recruit teams, and partner closely with founders to turn early discoveries into life-changing medicines.
Biotech venture is also one of the most fragmented areas of private markets research. Identifying which firms truly specialize in therapeutics, rather than generalist healthcare or broad tech investing, remains difficult. That is why we created this list: a curated view of 10 venture firms at the forefront of biotech and therapeutics, built around firm DNA (company creation vs. classic VC), modality focus, and consistent category leadership across multiple cycles.
Want full profiles, portfolios, funding history, stage focus, and therapeutic-area heatmaps for leading life sciences investors? Book a Dakota Demo at Dakota.com.
How We Selected the Top Biotech & Therapeutics Venture Firms
Rankings are based on:
- Depth of biotech and therapeutics specialization (not generalist “healthcare” coverage)
- Repeat company-building outcomes (formation, incubation, syndicate leadership)
- Track record across market cycles (platform creation plus durable exits)
- Modality leadership (cell and gene therapy, genomics, novel chemistry, AI-plus-biology platforms, and more)
- Ability to fund from seed through scale (or consistently syndicate and lead across rounds)
- Reputation for hands-on scientific partnership with founders and key opinion leaders (KOLs)
- Verified data sourced from Dakota Private Markets’ global GP intelligence ecosystem
This ensures the list reflects true biotech builders, not generalists with one or two opportunistic investments.
Top 10 Venture Firms Investing in Biotech & Therapeutics
1. Third Rock Ventures
Focus Areas: Company creation, transformational therapeutics, cell and gene therapy, platform biotechs
Why They’re Notable: Third Rock is one of the most proven biotech company builders, pairing deep scientific conviction with hands-on formation and early operating support to scale high-impact therapeutics from concept to clinic and beyond.
2. Flagship Pioneering
Focus Areas: Bioplatform innovation, venture creation, therapeutics and diagnostics, category-defining technologies
Why They’re Notable: Flagship is a leading venture creation engine in life sciences, repeatedly building new platforms from proprietary scientific “white space” and scaling companies designed to redefine entire categories.
View full portfolio inside Dakota Marketplace — Book a Dakota Demo
3. ARCH Venture Partners
Focus Areas: Deep-science therapeutics, gene editing, tools and diagnostics, frontier modalities
Why They’re Notable: ARCH is a cornerstone of high-risk, high-impact life sciences investing, backing foundational academic science with flexible capital that can start at seed and scale through large growth financings.
4. Atlas Venture
Focus Areas: Early-stage biotech formation, precision oncology, genomics, novel protein scaffolds, covalent chemistry, gene therapy
Why They’re Notable: Atlas invests exclusively in biotech and is formation-forward, with a long record of identifying differentiated scientific opportunities early and building companies with the discipline to become durable drug developers.
5. Versant Ventures
Focus Areas: Biotech company creation, therapeutics-first investing, academic translation, Discovery Engines
Why They’re Notable: Versant pairs deep scientific diligence with structured company creation, using dedicated internal teams to help validate academic discoveries and launch new ventures with speed and rigor.
6. Sofinnova Partners
Focus Areas: European life sciences (biopharma, medtech, industrial biotech), breakthrough science, long-duration innovation
Why They’re Notable: Sofinnova is one of Europe’s most established life sciences investors, combining decades of pattern recognition with a broad life sciences mandate and sustained support for ambitious science-driven companies.
View full portfolio inside Dakota Marketplace — Book a Dakota Demo
7. New Enterprise Associates (NEA)
Focus Areas: Healthcare and technology, biotech and therapeutics across stages, long-term scaling support
Why They’re Notable: NEA brings rare scale and consistency to life sciences, supporting biotech founders from early conviction through growth with a collaborative platform that helps companies recruit, fundraise, and scale strategically.
8. Vida Ventures
Focus Areas: Next-generation therapeutics, biomedical innovation, science-led company building
Why They’re Notable: Vida is built by scientific operators and investors focused on translating cutting-edge biology into therapeutics and platforms with meaningful clinical and patient impact, often leaning into novel mechanisms and differentiated approaches.
9. Andreessen Horowitz (a16z) Bio + Health
Focus Areas: AI and biology, biotech, digital health, next-generation care delivery, diagnostics and therapeutics
Why They’re Notable: a16z Bio + Health invests at the intersection of software and biology, backing founders building new health system primitives, data-driven biology platforms, and technology-enabled diagnostics and therapeutics.
10. Foresite Capital
Focus Areas: Data-driven biotech, techbio platforms, therapeutics and enabling tools, multi-stage investing
Why They’re Notable: Foresite is a leading techbio investor, using a data science-forward approach to back companies where computation and biology combine to accelerate discovery and transform healthcare.
View full portfolio inside Dakota Marketplace — Book a Dakota Demo
Biotech & Therapeutics Venture Trends to Watch in 2025
Biotech venture is increasingly defined by platform-building and modality innovation. Key themes driving activity include:
1. Techbio becomes default, not niche
AI-native discovery, large biological datasets, and computation-led biology increasingly define how new therapeutics are discovered and developed.
2. New modality competition accelerates
Cell therapy, gene therapy, RNA medicines, targeted protein degradation, and next-generation antibody formats continue to attract platform capital.
3. Company creation models keep compounding
Firms with internal incubators, operator benches, and repeat formation playbooks are compressing time-to-company and time-to-clinic.
4. Financing structures stay tighter and more milestone-driven
Syndicates are becoming more selective, with staged capital deployment tied to translational proof and early clinical signals.
5. Precision development becomes the standard
Clinical plans increasingly emphasize biomarker strategies, patient stratification, and higher-probability initial indications.
How We Know This
Dakota Private Markets tracks:
- GPs across venture, private equity, and private credit
- Fund histories and strategies
- Portfolio construction and deal activity
- Sector tagging and sub-sector heatmaps
- Stage focus, check sizes, and co-invest networks
- Private company intelligence, transactions, and ongoing updates
This biotech venture list is a small glimpse of the depth available inside Dakota Private Markets.
Ready to Explore the Full Biotech VC Landscape?
Thousands of investors, founders, and advisors rely on Dakota Private Markets to source deals faster, research smarter, and stay ahead of the market.
Book a demo of Dakota Marketplace.
